With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead Sciences, Hookipa Pharma has ...

Gilead has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

Merck & Co's Keytruda has become the first checkpoint inhibitor to help patients with advanced cervical cancer live longer when used as alongside standard first-line drugs. Keytruda (pembrolizumab ...

During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

Overview of Breast Cancer Therapeutics MarketThe Global Breast Cancer Therapeutics Market is valued at USD 33.83 Billion in ...

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

Hodgkin's lymphoma market size is expected to increase during the forecast period (2025–2034) owing to increasing incidence, advancements in ...

Gilead’s Trodelvy with Merck’s Keytruda cuts disease progression/ death in breast cancer SA NewsSat, May 31 2 Comments ...